Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

News
Sep 26, 2014 Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation »
Sep 19, 2014 Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting »
Sep 16, 2014 FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain »
Aug 21, 2014 Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients »
Latest and Upcoming Investor Events
Contact Nektar Investor Relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Contact
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877)290-2261
(201)680-6578
www.computershare.com/investor
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide